DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma
Portfolio Pulse from
Johnson & Johnson's DARZALEX FASPRO® shows a 51% reduction in risk of progression to active multiple myeloma for high-risk smoldering multiple myeloma patients, based on Phase 3 AQUILA study results.
December 08, 2024 | 4:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson's DARZALEX FASPRO® significantly reduces the risk of progression to active multiple myeloma, potentially boosting the company's stock due to positive Phase 3 AQUILA study results.
The Phase 3 AQUILA study results showing a 51% reduction in progression risk to active multiple myeloma for DARZALEX FASPRO® are significant. This positions JNJ's product as a leading treatment option, likely increasing investor confidence and potentially boosting the stock price.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90